MARKET

SRPT

SRPT

Sarepta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

74.57
-0.04
-0.05%
After Hours: 74.01 -0.56 -0.75% 18:38 05/07 EDT
OPEN
75.01
PREV CLOSE
74.61
HIGH
76.88
LOW
74.04
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
181.83
52 WEEK LOW
68.04
MARKET CAP
5.95B
P/E (TTM)
-8.3397
1D
5D
1M
3M
1Y
5Y
Heres Why Artisan Partners Disposed its Sarepta Therapeutics Inc. (SRPT) Position
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded here. A return of -2.36% was recorded by its Investor Class: ARTMX, -2.32% by its A...
Insider Monkey · 4h ago
Global Marburg Hemorrhagic Fever Drug ProfessionalSize, Share, Value, and Competitive Landscape 2020
Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional markets are estimated by market analyst, data analyst and people from related industry, based on companys’ revenue and applications ma...
Heraldkeepers · 13h ago
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday.
Benzinga · 16h ago
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Zacks.com · 1d ago
Oppenheimer Maintains a Hold Rating on Sarepta Therapeutics (SRPT)
In a report released today, Hartaj Singh from Oppenheimer maintained a Hold rating on Sarepta Therapeutics (SRPT). The company's shares closed last
SmarterAnalyst · 1d ago
Albireo Reports Q1 Financial Results and Business Update
BOSTON, May 06, May 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- - BylvayTM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and...
GlobeNewswire · 1d ago
Needham Thinks Sarepta Therapeutics’ Stock is Going to Recover
In a report released today, Chad Messer from Needham assigned a Buy rating to Sarepta Therapeutics (SRPT), with a price target of $166.00. The company's
SmarterAnalyst · 1d ago
Ebola Vaccine Market Remarkable Growth| Sarepta Therapeutics Inc, Mapp Biopharmaceutical Inc and Regeneron Pharmaceuticals Inc
May 06, 2021 (WiredRelease via Comtex) -- MarketResearch.Biz one of the world’s prominent marketing research firm has launched a brand new report on Global...
marketresearch.biz · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRPT. Analyze the recent business situations of Sarepta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRPT stock price target is 134.35 with a high estimate of 207.00 and a low estimate of 72.00.
EPS
Institutional Holdings
Institutions: 625
Institutional Holdings: 75.27M
% Owned: 94.37%
Shares Outstanding: 79.75M
TypeInstitutionsShares
Increased
123
2.96M
New
87
1.62M
Decreased
158
4.74M
Sold Out
41
893.08K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
M. Kathleen Behrens
President/Chief Executive Officer/Director
Douglas Ingram
Chief Financial Officer/Executive Vice President/Chief Accounting Officer
Ian Estepan
Executive Vice President
William Ciambrone
Executive Vice President
Alexander Cumbo
Executive Vice President
Gilmore O'Neill
Chief Scientific Officer
Louise Rodino-Klapac
General Counsel
Ryan Brown
Other
Dallan Murray
Independent Director
Richard Barry
Independent Director
Mary Gray
Independent Director
John Martin
Independent Director
Claude Nicaise
Independent Director
Hans Wigzell
No Data
About SRPT
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.